British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)
- PMID: 29054853
- DOI: 10.1136/thoraxjnl-2017-210927
British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)
Conflict of interest statement
Competing interests: JB has received honorarium funding from AZ. TC has received funding from Chiesi. AF has received funding from GSK. ARF has received funding from Insmed. CSH has received funding from Aradigm, Chiesi, Gilead, Insmed, Raptor, Teva, Vertex, Zambon. ML has received funding from Insmed, Pulmocide, Bayer, Chiesi and Raptor. RW has received funding from Bayer.
Comment in
-
Introducing the new BTS Guideline: Management of non-tuberculous mycobacterial pulmonary disease (NTM-PD).Thorax. 2017 Nov;72(11):969-970. doi: 10.1136/thoraxjnl-2017-210929. Thorax. 2017. PMID: 29054887
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical